An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

Roche

Status: Terminated

Conditions: Lymphoma, Follicular

Study type: Observational

Funder types: Industry

Identifiers

NCT01609036

ML22236

Details and patient eligibility

About

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years
• Patients with previously untreated follicular lymphoma (stage III-IV) according to the approved summary of product characteristics (SPC)

Exclusion criteria

• Contraindications to MabThera/Rituxan therapy according to the approved SPC

Trial design

3 participants in 1 patient group

Cohort